Loading…
BioNexus Gene Lab Corp. is projected to decline to $1.63 by 2027, a -10% move from its current price of $1.81. BGLC is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $1.72 | $1.81 | $1.90 | -0.05% |
| Jul 14 | $1.69 | $1.81 | $1.93 | -0.11% |
| Jul 15 | $1.66 | $1.81 | $1.96 | -0.16% |
| Jul 16 | $1.64 | $1.81 | $1.99 | -0.22% |
| Jul 17 | $1.62 | $1.81 | $2.01 | -0.27% |
| Jul 18 | $1.61 | $1.80 | $2.03 | -0.33% |
| Jul 19 | $1.59 | $1.80 | $2.05 | -0.38% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.59 | $1.80 | $2.05 | -0.38% |
| Week 2 | $1.50 | $1.80 | $2.15 | -0.76% |
| Week 3 | $1.44 | $1.79 | $2.23 | -1.14% |
| Week 4 | $1.38 | $1.78 | $2.29 | -1.52% |
| Week 5 | $1.34 | $1.78 | $2.35 | -1.89% |
| Week 6 | $1.30 | $1.77 | $2.41 | -2.27% |
| Week 7 | $1.26 | $1.76 | $2.46 | -2.64% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
BioNexus Gene Lab Corp. focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding.
It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company’s products are used in producing finished goods such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers.
BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
BioNexus Gene Lab Corp. (BGLC) is categorized in Basic Materials. The stock trades at current price $1.73 and has a market cap of $4.18M, ranking 5376 by size. The current technical picture shows bearish sentiment, with RSI(14) at 30 and moving averages at SMA50 $2.14 and SMA200 $3.28.
The 30-day range runs from $1.26 to $2.38, with a defined support at $1.73 and resistance at $2.61. The near-term price path and the multi-year forecast indicate a mixed to evolving outlook with potential long-run upside.
A major floor 35.4% below — a decisive break under it would weaken the trend.
The nearest floor, 4.4% below — buyers have tended to step in here.
The nearest ceiling, 44.2% above — a clean break opens room to run.
A major ceiling 61.9% above — clearing it would confirm fresh momentum.
Key BGLC support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BGLC market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.90 | Sell | $1.87 | Sell |
| MA 10 | $1.96 | Sell | $1.96 | Sell |
| MA 20 | $2.15 | Sell | $2.06 | Sell |
| MA 50 | $2.13 | Sell | $2.16 | Sell |
| MA 100 | $2.24 | Sell | $2.41 | Sell |
| MA 200 | $3.26 | Sell | $2.97 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.43 | Neutral |
| Stoch RSI (14) | 18.74 | Buy |
| CCI (20) | -104.90 | Sell |
| Williams %R (14) | -88.41 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -25.21 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 11.59 | Buy |
| TRIX (15) | -0.31 | Sell |
| Awesome (5,34) | -0.27 | Sell |
| Ultimate (7,14,28) | 33.98 | Neutral |
| Momentum (10) | -0.23 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 1.79 | Buy |
| ADX (14) | 17.91 | Neutral |
| ATR (14) | 0.09 | Info |
Near-term sentiment remains BEARISH with RSI(14) at 30. The 50-day moving average sits at $2.14, while the 200-day moving average sits at $3.28, signaling limited near-term momentum. The stock trades near established support at $1.73 and faces resistance at $2.61, within a 30-day range of $1.26–$2.38.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.73 | $1.81 | $2.21 | 0% | Neutral | |
| $1.21 | $1.63 | $2.38 | -10% | Neutral | |
| $1.16 | $1.65 | $2.55 | -9% | Neutral | |
| $0.9333 | $1.39 | $2.24 | -23% | Bearish | |
| $1.10 | $1.71 | $2.87 | -5% | Neutral | |
| $1.39 | $2.23 | $3.86 | +23% | Bullish | |
| $1.33 | $2.21 | $3.94 | +22% | Bullish | |
| $1.36 | $2.34 | $4.28 | +30% | Bullish | |
| $1.17 | $2.08 | $3.89 | +15% | Neutral | |
| $1.03 | $1.89 | $3.61 | +5% | Neutral | |
| $1.42 | $3.05 | $6.36 | +68% | Bullish | |
| $1.87 | $4.16 | $9.56 | +130% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $1.73 | $1.81 | $2.16 | +0.00% |
| August 2026 | $1.40 | $1.69 | $2.11 | -6.72% |
| September 2026 | $1.41 | $1.72 | $2.19 | +1.99% |
| October 2026 | $1.42 | $1.76 | $2.27 | +2.01% |
| November 2026 | $1.35 | $1.68 | $2.20 | -4.51% |
| December 2026 | $1.33 | $1.66 | $2.21 | -0.81% |
Click any year to see its month-by-month BGLC forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BGLC to range from $1.73 to $2.21 through 2026. The $1.81 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BGLC price prediction for 2027 points to an average of $1.63 (low $1.21, high $2.38) — a potential decline of -10% on today's $1.81. Price action looks broadly range-bound.
In 2028, BGLC is projected to trade between $1.16 and $2.55, averaging $1.65 — a potential decline of -9% from today's $1.81. That is up +1% on the projected 2027 average. A consolidation phase looks the most probable path here.
BioNexus Gene Lab Corp.'s 2029 outlook centres on $1.39, within a $0.9333 to $2.24 range. That is -16% versus the projected 2028 average. That marks a -23% change versus current levels. A cyclical pullback looks likely — prices rarely move in a straight line.
By 2030, BGLC could reach as high as $2.87, with a base case around $1.71 and support toward $1.10 — roughly -5% from $1.81. A consolidation phase looks the most probable path here.
Expect BGLC to range from $1.39 to $3.86 through 2031. The $2.23 average target implies a +23% move from current prices. That is up +31% on the projected 2030 average. Momentum favours further upside here.
The BGLC price prediction for 2032 points to an average of $2.21 (low $1.33, high $3.94) — a potential gain of +22% on today's $1.81. Buyers look set to stay in control over this stretch.
In 2033, BGLC is projected to trade between $1.36 and $4.28, averaging $2.34 — a potential gain of +30% from today's $1.81. That is up +6% on the projected 2032 average. Momentum favours further upside here.
BioNexus Gene Lab Corp.'s 2034 outlook centres on $2.08, within a $1.17 to $3.89 range. That is -11% versus the projected 2033 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2035, BGLC could reach as high as $3.61, with a base case around $1.89 and support toward $1.03 — roughly +5% from $1.81. Price action looks broadly range-bound.
Expect BGLC to range from $1.42 to $6.36 through 2040. The $3.05 average target implies a +68% move from current prices. That is up +61% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BGLC price prediction for 2050 points to an average of $4.16 (low $1.87, high $9.56) — a potential gain of +130% on today's $1.81. Momentum favours further upside here.
Investing $1,000 in BGLC today (≈ 552.486188 BGLC) could be worth
$2,297.49
+$1,297.49 (+130%) by 2050 · US Dollar
Based on the average projected BGLC price of $4.16 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BGLCwould be worth at today's price.
$1,000 invested in BGLC on Jul 10, 2025 (≈ 165.562915 BGLC) would be worth
$299.67
-$700.33 (-70.0%) today · 0.30× · US Dollar
Based on a BGLC entry price of $6.04 vs. today's $1.81.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.03 | $891.63 | -10.8% |
| 1 month ago | $1.97 | $918.78 | -8.1% |
| 3 months ago | $2.18 | $830.28 | -17.0% |
| 6 months ago | $3.75 | $482.67 | -51.7% |
| 1 year ago | $6.04 | $299.67 | -70.0% |
| All time (5.0y) ago | $207.6 | $8.72 | -99.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BGLC forecast.
Our base-case forecast reaches $3.60 around 2050.
Implied market cap at $3.60: $8.7M
The multi-year forecast shows a mixed path with near-term Neutral to Bearish signals and eventual upside. In 2026 the average price is $1.73 with a neutral stance and a max of $2.12, while 2027–2029 enter bearish territory with 2027 avg $1.56, max $2.27, and 2029 avg $1.31, max $2.11. The 2030 forecast projects an average of $1.59 with a negative ROI of -8.3 and Neutral sentiment.
From 2031 onward, the outlook improves: 2031 avg $2.07 with ROI 19.9, 2032 avg $2.07 with ROI 19.8, and 2033 avg $2.19 with ROI 26.6, followed by 2034 avg $1.94 (ROI 11.9) and 2035 avg $1.77 (ROI 2.2). The long-run forecast turns decisively bullish in 2040 with avg $2.81 and ROI 62.6, and again in 2050 with avg $3.81 and ROI 120.2, both marked as BULLISH.
Tap a question to reveal the answer.
The forecast shows 2030 avg $1.59 with ROI -8.3 and Neutral sentiment; the range for 2030 is min $1.02 and max $2.66.
Near-term indicators are Neutral to Bearish with the stock at $1.73 and a bearish RSI of 30. The multi-year forecast turns bullish later, with 2040 avg $2.81 (ROI 62.6) and 2050 avg $3.81 (ROI 120.2), but these are not guarantees.
According to the forecast, 2035 avg $1.77 with max $3.38 and ROI 2.2; the 2035 max does not reach $4.
Current price is $1.73 and market cap is $4.18M.
Bullish sentiment appears in 2033 (avg $2.19, ROI 26.6) and strengthens in 2040 (avg $2.81, ROI 62.6) and 2050 (avg $3.81, ROI 120.2).
BioNexus Gene Lab Corp. Community Discussion
0Share your BioNexus Gene Lab Corp. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.